FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009096079> ?p ?o ?g. }

• W2009096079 endingPage "380" @default.
• W2009096079 startingPage "374" @default.
• W2009096079 abstract "Objective To evaluate the progression-free rate (PFR) at 3 months (13 ± 1 weeks), antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h continuous i.v. infusion at a dose of 5 mg/m2, every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC). Patients and methods This was a multicenter, non-randomized, exploratory, phase II study. Treatment lasted until disease progression, unacceptable toxicity, patient refusal or treatment delay for >2 weeks. PFR (primary efficacy endpoint) and objective response rate (secondary efficacy endpoint) were evaluated according to RECIST, while the toxic profile of plitidepsin was assessed using the NCI-CTC, version 2.0. Results A total of 21 patients with a median age of 61 years and with locally advanced or metastatic non-resectable NSCLC, who had previously received only one line of chemotherapy in an advanced setting, received a total of 54 cycles of treatment (median of two cycles per patient; range: 1–8). Antitumor activity was seen in 3 (1 PR, 2 SD) out of 17 evaluable patients according to RECIST. One patient was responder for the primary (PFR at 13 ± 1 weeks) and secondary efficacy endpoint (stable disease according to RECIST). Other two patients were non-responders for the primary efficacy endpoint, but had stable disease (not confirmed at weeks 13 ± 1 due to previous withdrawal due to adverse events). With a median follow-up of 12.3 months, the median time to progression (TTP) and the median overall survival (OS) were 1.2 months and 4.3 months, respectively. The incidence of plitidepsin-related toxicities was low and most of them were mild-to-moderate in severity. The most common side effects were anemia, and asymptomatic and non-cumulative increases of gamma-glutamyltransferase (GGT) and liver transaminase levels. Conclusion This study shows that plitidepsin 3-h continuous i.v. infusion (5 mg/m2) every 2 weeks, was feasible and well tolerated in patients with pretreated NSCLC. The lack of evidence of antitumor activity precludes further studies with this plitidepsin schedule in this tumor setting." @default.
• W2009096079 created "2016-06-24" @default.
• W2009096079 creator A5005474411 @default.
• W2009096079 creator A5030556621 @default.
• W2009096079 creator A5046413239 @default.
• W2009096079 creator A5050857187 @default.
• W2009096079 creator A5052177007 @default.
• W2009096079 creator A5066200247 @default.
• W2009096079 creator A5066640097 @default.
• W2009096079 creator A5075656335 @default.
• W2009096079 creator A5078383767 @default.
• W2009096079 creator A5087396382 @default.
• W2009096079 date "2008-06-01" @default.
• W2009096079 modified "2023-10-18" @default.
• W2009096079 title "Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer" @default.
• W2009096079 cites W1964234385 @default.
• W2009096079 cites W1964356886 @default.
• W2009096079 cites W1976843162 @default.
• W2009096079 cites W2029409133 @default.
• W2009096079 cites W2038212467 @default.
• W2009096079 cites W2043450431 @default.
• W2009096079 cites W2059645245 @default.
• W2009096079 cites W2075351817 @default.
• W2009096079 cites W2106708030 @default.
• W2009096079 cites W2125540170 @default.
• W2009096079 cites W2130030010 @default.
• W2009096079 cites W2130652363 @default.
• W2009096079 cites W2133297306 @default.
• W2009096079 cites W2134667653 @default.
• W2009096079 cites W2139248078 @default.
• W2009096079 cites W2145653040 @default.
• W2009096079 cites W2156792347 @default.
• W2009096079 cites W2163188114 @default.
• W2009096079 cites W2169363650 @default.
• W2009096079 cites W2226490553 @default.
• W2009096079 doi "https://doi.org/10.1016/j.lungcan.2007.10.019" @default.
• W2009096079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18054408" @default.
• W2009096079 hasPublicationYear "2008" @default.
• W2009096079 type Work @default.
• W2009096079 sameAs 2009096079 @default.
• W2009096079 citedByCount "24" @default.
• W2009096079 countsByYear W20090960792012 @default.
• W2009096079 countsByYear W20090960792013 @default.
• W2009096079 countsByYear W20090960792014 @default.
• W2009096079 countsByYear W20090960792015 @default.
• W2009096079 countsByYear W20090960792017 @default.
• W2009096079 countsByYear W20090960792018 @default.
• W2009096079 countsByYear W20090960792019 @default.
• W2009096079 countsByYear W20090960792023 @default.
• W2009096079 crossrefType "journal-article" @default.
• W2009096079 hasAuthorship W2009096079A5005474411 @default.
• W2009096079 hasAuthorship W2009096079A5030556621 @default.
• W2009096079 hasAuthorship W2009096079A5046413239 @default.
• W2009096079 hasAuthorship W2009096079A5050857187 @default.
• W2009096079 hasAuthorship W2009096079A5052177007 @default.
• W2009096079 hasAuthorship W2009096079A5066200247 @default.
• W2009096079 hasAuthorship W2009096079A5066640097 @default.
• W2009096079 hasAuthorship W2009096079A5075656335 @default.
• W2009096079 hasAuthorship W2009096079A5078383767 @default.
• W2009096079 hasAuthorship W2009096079A5087396382 @default.
• W2009096079 hasConcept C126322002 @default.
• W2009096079 hasConcept C141071460 @default.
• W2009096079 hasConcept C143998085 @default.
• W2009096079 hasConcept C197934379 @default.
• W2009096079 hasConcept C203092338 @default.
• W2009096079 hasConcept C2776256026 @default.
• W2009096079 hasConcept C2776694085 @default.
• W2009096079 hasConcept C2778822529 @default.
• W2009096079 hasConcept C2779984678 @default.
• W2009096079 hasConcept C29730261 @default.
• W2009096079 hasConcept C31760486 @default.
• W2009096079 hasConcept C535046627 @default.
• W2009096079 hasConcept C71924100 @default.
• W2009096079 hasConcept C90924648 @default.
• W2009096079 hasConceptScore W2009096079C126322002 @default.
• W2009096079 hasConceptScore W2009096079C141071460 @default.
• W2009096079 hasConceptScore W2009096079C143998085 @default.
• W2009096079 hasConceptScore W2009096079C197934379 @default.
• W2009096079 hasConceptScore W2009096079C203092338 @default.
• W2009096079 hasConceptScore W2009096079C2776256026 @default.
• W2009096079 hasConceptScore W2009096079C2776694085 @default.
• W2009096079 hasConceptScore W2009096079C2778822529 @default.
• W2009096079 hasConceptScore W2009096079C2779984678 @default.
• W2009096079 hasConceptScore W2009096079C29730261 @default.
• W2009096079 hasConceptScore W2009096079C31760486 @default.
• W2009096079 hasConceptScore W2009096079C535046627 @default.
• W2009096079 hasConceptScore W2009096079C71924100 @default.
• W2009096079 hasConceptScore W2009096079C90924648 @default.
• W2009096079 hasIssue "3" @default.
• W2009096079 hasLocation W20090960791 @default.
• W2009096079 hasLocation W20090960792 @default.
• W2009096079 hasOpenAccess W2009096079 @default.
• W2009096079 hasPrimaryLocation W20090960791 @default.
• W2009096079 hasRelatedWork W1584669207 @default.
• W2009096079 hasRelatedWork W2009096079 @default.
• W2009096079 hasRelatedWork W2024340610 @default.
• W2009096079 hasRelatedWork W2024938637 @default.
• W2009096079 hasRelatedWork W2121180524 @default.

• next